Annual report pursuant to Section 13 and 15(d)

Stockholders??? Equity

v3.21.1
Stockholders’ Equity
12 Months Ended
Jan. 02, 2021
Stockholders Equity Note [Abstract]  
Stockholders’ Equity

Note 17:

  Stockholders’ Equity

Common Stock: Our Articles of Incorporation authorize 200,000,000 shares of common stock that may be issued from time to time having such rights, powers, preferences and designations as the Board of Directors may determine.

 

On November 4, 2020, at the Company’s Annual Meeting of Stockholders (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “Charter Amendment”) to the Company’s Articles of Incorporation to increase the total number of authorized shares of the Company’s common stock from 10,000,000 shares to 200,000,000 shares.  Following stockholder approval, the Charter Amendment was filed with the Nevada Secretary of State on November 5, 2020, at which time the Charter Amendment became effective.  The Company’s Board of Directors had previously approved the Charter Amendment, subject to stockholder approval.  The description of the Charter Amendment is qualified in its entirety by reference to the complete text of the Charter Amendment, a copy of which is filed as Exhibit 3.10 to the Company’s Quarterly Report on Form 10-Q for the period ended September 26, 2020 and is incorporated herein by reference.

During fiscal year 2020, 104,798 shares of common stock were granted and issued in lieu of professional services at a fair value of $351. During fiscal year 2019, 224,483 common shares were issued as compensation to employees and consultants with a fair value of $500. Additionally, the Company recognized stock compensation expense of $54 and $131 during the years ended January 2, 2021 and December 31, 2019, respectively, related to the amortization of the fair value of shares of its common stock vesting and/or issued for services rendered.  

As of January 2, 2021, and December 28, 2019, there were 1,829,982 and 1,919,048  shares, respectively, of common stock issued and outstanding.

 

Stock options: The 2016 Plan, which replaces the 2011 Plan, authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October 28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On November 4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from 400,000 to 800,000. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of January 2, 2021 and December 28, 2019, 78,000 and 4,000, respectively, options were outstanding under the 2016 Plan.

Our 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expires on the earlier of May 12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of January 2, 2021 and December 28, 2019, 35,900 and 40,400 options, respectively, were outstanding under the 2011 Plan. No additional awards will be granted under the 2011 Plan.

The following table summarizes stock option activity for fiscal 2020 and 2019:

 

 

 

Options

 

 

Weighted

Average

Exercise

 

 

Aggregate

Intrinsic

 

 

Weighted

Average

Remaining

Contractual

 

 

 

Outstanding

 

 

Price

 

 

Value

 

 

Life

 

Outstanding at December 29, 2018

 

 

100,900

 

 

$

11.07

 

 

$

 

 

 

3.8

 

Cancelled/expired

 

 

(56,500

)

 

 

9.30

 

 

 

 

 

 

 

 

 

Outstanding at December 28, 2019

 

 

44,400

 

 

$

13.31

 

 

$

 

 

 

3.0

 

Cancelled/expired

 

 

(4,500

)

 

 

9.45

 

 

 

 

 

 

 

 

 

Granted

 

 

74,000

 

 

 

3.84

 

 

 

 

 

 

 

 

 

Outstanding at January 2, 2021

 

 

113,900

 

 

$

11.97

 

 

$

78

 

 

 

7.0

 

Exercisable at January 2, 2021

 

 

65,400

 

 

$

12.01

 

 

$

27

 

 

 

3.0

 

 

The exercise price for stock options outstanding and exercisable outstanding at January 2, 2021 is as follows:

 

Outstanding

 

Exercisable

Number of Options

 

 

Exercise Price ($)

 

Number of Options

 

 

Exercise Price ($)

 

16,500

 

 

$17.35 to $23.45

 

 

16,500

 

 

$17.35 to $23.45

 

5,400

 

 

$11.10 to $15.00

 

 

5,400

 

 

$11.10 to $15.00

 

12,000

 

 

$5.70 to $9.90

 

 

12,000

 

 

$5.70 to $9.90

 

80,000

 

 

$3.54 to $5.25

 

 

31,500

 

 

$3.54 to $5.25

 

113,900

 

 

 

 

 

65,400

 

 

 

 

The following table summarizes information about the Company’s non-vested shares outstanding as of January 2, 2021 and December 28, 2019:

 

Non-vested Shares

 

Number of

Shares

 

 

Average

Grant-Date

Fair Value

 

Non-vested at December 29, 2018

 

 

 

 

$

 

Granted

 

 

 

 

$

 

Vested

 

 

 

 

$

 

Non-vested at December 28, 2019

 

 

 

 

$

 

Granted

 

 

74,000

 

 

$

3.09

 

Vested

 

 

(25,500

)

 

$

3.85

 

Non-vested at January 2, 2021

 

 

48,500

 

 

$

3.83

 

We recognized share-based compensation expense related to stock options of $173 and $nil for fiscal years 2020 and 2019, respectively. At January 2, 2021, the Company has $55 of unrecognized compensation expense (net of estimated forfeitures) associated with stock option awards which the company expects to recognize as compensation expense through December 2021.

Warrants:

As of January 2, 2021 and December 28, 2019, there were 33,363 warrants outstanding to purchase 33,363 shares of common stock at a price of $3.40 per share that expire in November 2021.